Skip to content
AnalystLens

Idex Annual Report, Year Ended Dec 31, 2023

Filing Date
Filed February 22, 2024
Period End
December 31, 2023
Security
IEX
One revenue dollarkept$0.18
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Apr ’20Apr ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation (IEX) reported 2023 net sales of $3,273.9 milliona, up 3% from $3,181.9 million in 2022, with organic net sales declining 1%.

Net income attributable to IDEX was $596.1 millionb, up 2%, and diluted EPS was $7.85 versus $7.71. Adjusted EBITDA rose 2% to $899.6 million, and the company generated record free cash flow of $626.8 million on operating cash flow of $716.7 million. Growth was driven by a 5% contribution from acquisitions net of divestitures and price capture, partially offset by lower volumes, particularly in the Health & Science Technologies segment, as customers destocked inventory.

The company operates three reportable segments: Fluid & Metering Technologies (42% of segment Adjusted EBITDA), Health & Science Technologies (37%), and Fire & Safety/Diversified Products (21%). During 2023 IDEX acquired Iridian Spectral Technologies for $109.8 millionc and STC Material Solutions for $202.0 million, and sold Micropump for $110.3 million, recording a pre-tax gain of $93.8 million. Total borrowings were $1,333.3 million at year-end, with cash and cash equivalents of $534.3 million, and the company was in compliance with its financial covenants, with an interest coverage ratio of 18.43 to 1 and a leverage ratio of 1.45 to 1.

Management stated that the majority of its businesses were seeing stable demand and early signs of improvement, particularly in Fluid & Metering Technologies, while life sciences and analytical instrument markets were not yet showing near-term recovery. The Dispensing reporting unit is expected to contract in 2024 following completion of a North American fleet refreshment cycle in 2023.

Key Highlights

  1. Net sales rose 3% to $3,273.9 million; organic net sales declined 1% as lower volumes offset price capture.
  2. Net income attributable to IDEX was $596.1 million, up 2%, with diluted EPS of $7.85 versus $7.71 in 2022.
  3. Adjusted EBITDA reached $899.6 million, with margin of 27.5% versus 27.9% in 2022.
  4. Operating cash flow was $716.7 million, up from $557.4 million, and record free cash flow was $626.8 million.
  5. Acquired Iridian ($109.8 million) and STC ($202.0 million); sold Micropump for $110.3 million with a $93.8 million pre-tax gain.
  6. Health & Science Technologies adjusted EBITDA fell 13% to $359.5 million as customer destocking reduced volumes.
  7. Quarterly dividend increased 7% from $0.60 to $0.64 per share; $539.7 million remained under the share repurchase authorization.

Follow one dollar

Of each $1.00 of revenue in FY2023, Idex kept $0.18.

  1. Revenue$3.27B100.0%
  2. Cost of revenue−$1.83B55.8%
  3. Gross profit$1.45B44.2%
  4. Operating costs−$714.4M21.8%
  5. Operating income$732.5M22.4%
  6. Interest, other & tax−$136.9M4.2%
  7. Net income$595.6M18.2%
Computed from 10-KFY2023filed February 22, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

FY2023 against FY2022

Line itemFY2023FY2022Change
Revenue$3.27B$3.18B+2.9%
Cost of Revenue$1.83B$1.75B+4.1%
Gross Profit$1.45B$1.43B+1.4%
R&D Expenses$68.40M$61.40M+11.4%
SG&A Expenses$703.50M$652.70M+7.8%
Operating Income$732.50M$751.40M−2.5%
Interest Expense$51.70M$40.70M+27.0%
Net Income$595.60M$586.70M+1.5%
EPS (Basic)$7.87$7.74+1.7%
EPS (Diluted)$7.85$7.71+1.8%
Shares Outstanding (Basic)75.60M75.70M−0.1%
Shares Outstanding (Diluted)75.90M76.00M−0.1%

Frequently Asked Questions

  1. How did IDEX perform in 2023 and what drove results?

    Net sales grew 3% to $3,273.9 million, driven by a 5% contribution from acquisitions net of divestitures and price capture across all segments. Organic sales declined 1% due to lower volumes from customer inventory recalibration, particularly in Health & Science Technologies. Net income attributable to IDEX increased 2% to $596.1 million.

  2. How strong is IDEX's cash generation and balance sheet?

    Cash flows from operating activities were $716.7 million, up from $557.4 million, reflecting lower working capital requirements. Free cash flow was $626.8 million. At year-end, the company held $534.3 million in cash and cash equivalents, $1,333.3 million in total borrowings, and $715.6 million of Revolving Facility availability.

  3. What is the outlook for 2024?

    Management said most businesses were experiencing stable demand with early signs of improvement, particularly in Fluid & Metering Technologies. Life sciences and analytical instrument markets, served by about one-third of Health & Science Technologies, appeared stable but were not yet showing near-term recovery. The Dispensing reporting unit is expected to contract in 2024, partly offset by growth in emerging markets and in the Fire & Safety and BAND-IT reporting units.

  4. What acquisitions and divestitures did IDEX complete in 2023?

    IDEX acquired Iridian Spectral Technologies in May for $109.8 million and STC Material Solutions in December for $202.0 million, both funded with cash on hand. It sold Micropump on August 3, 2023 for $110.3 million net of cash remitted, recording a pre-tax gain of $93.8 million, and sold Novotema on December 29, 2023 for $8.3 million, recording a loss of $9.1 million.

  5. What are the main risks flagged in the filing?

    Risk factors include slowdowns in U.S. or global economies, foreign currency fluctuations (50% of 2023 sales were international), rising interest rates on floating-rate debt, cybersecurity incidents, the ability to execute and integrate acquisitions, raw material and supply chain disruptions, and potential goodwill and intangible asset impairments, which totaled $2,838.3 million and $1,011.8 million respectively at year-end.